Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

A highly collaborative investment professional and US software research analyst with 10+ years of international experience in equity research, treasury operations, and trading positions across multiple asset classes at leading multinational banks Citibank and Morgan Stanley, UHNWI-backed family office and European independent equity research firm. A respectable background in equity capital markets, corporate treasury, investment banking operations, equity research analysis and portfolio management.

Is It Time For Moderna To Boost Share Buyback And Start Paying Dividends?

Gravity Works As WeWork Doesn't; Now Plan B

Algosun Global

Equity Bottom-Up

<ul>
<li>Leading mRNA vaccine producers announced plans to build manufacturing facilities in Africa this year. </li>
<li>According to Reuters, Rwanda, Senegal, or South Africa may be potential locations for Moderna’s new vaccine factory.</li>
<li>Africa has the world’s lowest vaccination rate, and only ~5% of Africans are fully vaccinated today. </li>
</ul>


Leading mRNA vaccine producers announced plans to build manufacturing facilities in Africa this year. 
According to Reuters, Rwanda, Senegal, or South Africa may be potential locations for Moderna’s new vaccine factory.
Africa has the world’s lowest vaccination rate, and only ~5% of Africans are fully vaccinated today. 


Why Moderna And BioNTech Want To Boost Production Capacities In Africa?